JP Morgan: Pricing agreement between Novo Nordisk and the White House will boost sales.

After a conversation with Nord Nord Chief Executive Officer Maziar Mike Doustdar, JPMorgan Chase stated that investors in Nord Nord need to consider that the White House drug pricing agreement will drag down the group's growth by low single-digit percentages. The bank stated that Doustdar indicated that the White House agreement on pricing for U.S. federal health insurance will boost sales growth, which should start to show in mid-2026 and be enough to offset the impact of price reductions. However, there may be a lag between price reductions and subsequent sales growth. The bank added that generic versions of Nord Nord drugs in multiple markets could also pose a potential downside to the group's growth. JPMorgan Chase said that despite indications of a slowdown in the growth of branded drugs, Doustdar emphasized that some patients using branded drugs may still be unable to afford approved drugs.